In contrast to the lower frequency of TP53 alterations (27.9%) in glioblastoma, the deletion of the CDKN2A gene, which codes for p16INK4a and p14ARF, was observed in a higher percentage of cases (57.8%), with mutations affecting Rb function being reported in up to 78.9% of cases [32]. The gene discussed is CDKN2A; the disease is glioblastoma.